Skip to main content
Erschienen in: Diabetologia 5/2012

01.05.2012 | Article

Hyperglycaemia normalises insulin action on glucose metabolism but not the impaired activation of AKT and glycogen synthase in the skeletal muscle of patients with type 2 diabetes

verfasst von: B. F. Vind, J. B. Birk, S. G. Vienberg, B. Andersen, H. Beck-Nielsen, J. F. P. Wojtaszewski, K. Højlund

Erschienen in: Diabetologia | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

In type 2 diabetes, reduced insulin-stimulated glucose disposal, primarily glycogen synthesis, is associated with defective insulin activation of glycogen synthase (GS) in skeletal muscle. Hyperglycaemia may compensate for these defects, but to what extent it involves improved insulin signalling to glycogen synthesis remains to be clarified.

Methods

Whole-body glucose metabolism was studied in 12 patients with type 2 diabetes, and 10 lean and 10 obese non-diabetic controls by means of indirect calorimetry and tracers during a euglycaemic-hyperinsulinaemic clamp. The diabetic patients underwent a second isoglycaemic-hyperinsulinaemic clamp maintaining fasting hyperglycaemia. Muscle biopsies from m. vastus lateralis were obtained before and after the clamp for examination of GS and relevant insulin signalling components.

Results

During euglycaemia, insulin-stimulated glucose disposal, glucose oxidation and non-oxidative glucose metabolism were reduced in the diabetic group compared with both control groups (p < 0.05). This was associated with impaired insulin-stimulated GS and AKT2 activity, deficient dephosphorylation at GS sites 2 + 2a, and reduced Thr308 and Ser473 phosphorylation of AKT. When studied under hyperglycaemia, all variables of insulin-stimulated glucose metabolism were normalised compared with the weight-matched controls. However, insulin activation and dephosphorylation (site 2 + 2a) of GS as well as activation of AKT2 and phosphorylation at Thr308 and Ser473 remained impaired (p < 0.05).

Conclusions/interpretations

These data confirm that hyperglycaemia compensates for decreased whole-body glucose disposal in type 2 diabetes. In contrast to previous less well-controlled studies, we provide evidence that the compensatory effect of hyperglycaemia in patients with type 2 diabetes does not involve normalisation of insulin action on GS or upstream signalling in skeletal muscle.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG (1990) Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13 C nuclear magnetic resonance spectroscopy. N Engl J Med 322:223–228PubMedCrossRef Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG (1990) Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13 C nuclear magnetic resonance spectroscopy. N Engl J Med 322:223–228PubMedCrossRef
2.
Zurück zum Zitat Cusi K, Maezono K, Osman A et al (2000) Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311–320PubMedCrossRef Cusi K, Maezono K, Osman A et al (2000) Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311–320PubMedCrossRef
3.
Zurück zum Zitat Højlund K, Staehr P, Hansen BF et al (2003) Increased phosphorylation of skeletal muscle glycogen synthase at NH2-terminal sites during physiological hyperinsulinemia in type 2 diabetes. Diabetes 52:1393–1402PubMedCrossRef Højlund K, Staehr P, Hansen BF et al (2003) Increased phosphorylation of skeletal muscle glycogen synthase at NH2-terminal sites during physiological hyperinsulinemia in type 2 diabetes. Diabetes 52:1393–1402PubMedCrossRef
4.
Zurück zum Zitat Højlund K, Frystyk J, Levin K, Flyvbjerg A, Wojtaszewski JF, Beck-Nielsen H (2006) Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 49:1283–1291PubMedCrossRef Højlund K, Frystyk J, Levin K, Flyvbjerg A, Wojtaszewski JF, Beck-Nielsen H (2006) Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 49:1283–1291PubMedCrossRef
5.
Zurück zum Zitat Højlund K, Beck-Nielsen H (2006) Impaired glycogen synthase activity and mitochondrial dysfunction in skeletal muscle. Markers or mediators of insulin resistance in type 2 diabetes. Curr Diabetes Rev 2:375–395PubMed Højlund K, Beck-Nielsen H (2006) Impaired glycogen synthase activity and mitochondrial dysfunction in skeletal muscle. Markers or mediators of insulin resistance in type 2 diabetes. Curr Diabetes Rev 2:375–395PubMed
6.
Zurück zum Zitat Højlund K, Glintborg D, Andersen NR et al (2008) Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 57:357–366PubMedCrossRef Højlund K, Glintborg D, Andersen NR et al (2008) Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 57:357–366PubMedCrossRef
7.
Zurück zum Zitat Højlund K, Birk JB, Klein DK et al (2009) Dysregulation of glycogen synthase COOH- and NH2-terminal phosphorylation by insulin in obesity and type 2 diabetes mellitus. J Clin Endocrinol Metab 94:4547–4556PubMedCrossRef Højlund K, Birk JB, Klein DK et al (2009) Dysregulation of glycogen synthase COOH- and NH2-terminal phosphorylation by insulin in obesity and type 2 diabetes mellitus. J Clin Endocrinol Metab 94:4547–4556PubMedCrossRef
8.
Zurück zum Zitat Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB (1999) Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104:733–741PubMedCrossRef Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB (1999) Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104:733–741PubMedCrossRef
9.
Zurück zum Zitat Glintborg D, Højlund K, Andersen NR, Hansen BF, Beck-Nielsen H, Wojtaszewski JF (2008) Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. J Clin Endocrinol Metab 93:3618–3626PubMedCrossRef Glintborg D, Højlund K, Andersen NR, Hansen BF, Beck-Nielsen H, Wojtaszewski JF (2008) Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. J Clin Endocrinol Metab 93:3618–3626PubMedCrossRef
10.
Zurück zum Zitat Damsbo P, Vaag A, Hother-Nielsen O, Beck-Nielsen H (1991) Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34:239–245PubMedCrossRef Damsbo P, Vaag A, Hother-Nielsen O, Beck-Nielsen H (1991) Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34:239–245PubMedCrossRef
11.
Zurück zum Zitat Karlsson HK, Zierath JR, Kane S, Krook A, Lienhard GE, Wallberg-Henriksson H (2005) Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 54:1692–1697PubMedCrossRef Karlsson HK, Zierath JR, Kane S, Krook A, Lienhard GE, Wallberg-Henriksson H (2005) Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 54:1692–1697PubMedCrossRef
12.
Zurück zum Zitat Adams JM II, Pratipanawatr T, Berria R et al (2004) Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53:25–31PubMedCrossRef Adams JM II, Pratipanawatr T, Berria R et al (2004) Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53:25–31PubMedCrossRef
13.
Zurück zum Zitat Morino K, Petersen KF, Dufour S et al (2005) Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 115:3587–3593PubMedCrossRef Morino K, Petersen KF, Dufour S et al (2005) Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 115:3587–3593PubMedCrossRef
14.
Zurück zum Zitat O'Gorman DJ, Karlsson HK, McQuaid S et al (2006) Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes. Diabetologia 49:2983–2992PubMedCrossRef O'Gorman DJ, Karlsson HK, McQuaid S et al (2006) Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes. Diabetologia 49:2983–2992PubMedCrossRef
15.
Zurück zum Zitat Beeson M, Sajan MP, Dizon M et al (2003) Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes 52:1926–1934PubMedCrossRef Beeson M, Sajan MP, Dizon M et al (2003) Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes 52:1926–1934PubMedCrossRef
16.
Zurück zum Zitat Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM (2005) Increased p85/55/50 expression and decreased phosphatidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54:2351–2359PubMedCrossRef Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM (2005) Increased p85/55/50 expression and decreased phosphatidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54:2351–2359PubMedCrossRef
17.
Zurück zum Zitat Kelley DE, Mandarino LJ (1990) Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. J Clin Invest 86:1999–2007PubMedCrossRef Kelley DE, Mandarino LJ (1990) Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. J Clin Invest 86:1999–2007PubMedCrossRef
18.
Zurück zum Zitat Mandarino L, Consoli A, Kelley DE, Reilly JJ, Nurjhan N (1990) Fasting hyperglycemia normalizes oxidative and nonoxidative pathways of insulin-stimulated glucose metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 71:1544–1551PubMedCrossRef Mandarino L, Consoli A, Kelley DE, Reilly JJ, Nurjhan N (1990) Fasting hyperglycemia normalizes oxidative and nonoxidative pathways of insulin-stimulated glucose metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 71:1544–1551PubMedCrossRef
19.
Zurück zum Zitat Thorburn AW, Gumbiner B, Bulacan F, Wallace P, Henry RR (1990) Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 85:522–529PubMedCrossRef Thorburn AW, Gumbiner B, Bulacan F, Wallace P, Henry RR (1990) Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 85:522–529PubMedCrossRef
20.
Zurück zum Zitat Revers RR, Fink R, Griffin J, Olefsky JM, Kolterman OG (1984) Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 73:664–672PubMedCrossRef Revers RR, Fink R, Griffin J, Olefsky JM, Kolterman OG (1984) Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 73:664–672PubMedCrossRef
21.
Zurück zum Zitat Vaag A, Damsbo P, Hother-Nielsen Beck-Nielsen H (1992) Hyperglycaemia compensates for the defects in insulin-mediated glucose metabolism and in the activation of glycogen synthase in the skeletal muscle of patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:80–88PubMedCrossRef Vaag A, Damsbo P, Hother-Nielsen Beck-Nielsen H (1992) Hyperglycaemia compensates for the defects in insulin-mediated glucose metabolism and in the activation of glycogen synthase in the skeletal muscle of patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:80–88PubMedCrossRef
22.
Zurück zum Zitat Cohen P, Alessi DR, Cross DA (1997) PDK1, one of the missing links in insulin signal transduction? FEBS Lett 410:3–10PubMedCrossRef Cohen P, Alessi DR, Cross DA (1997) PDK1, one of the missing links in insulin signal transduction? FEBS Lett 410:3–10PubMedCrossRef
23.
Zurück zum Zitat Klip A (2009) The many ways to regulate glucose transporter 4. Appl Physiol Nutr Metab 34:481–487PubMedCrossRef Klip A (2009) The many ways to regulate glucose transporter 4. Appl Physiol Nutr Metab 34:481–487PubMedCrossRef
24.
Zurück zum Zitat Thorburn AW, Gumbiner B, Bulacan F, Brechtel G, Henry RR (1991) Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest 87:489–495PubMedCrossRef Thorburn AW, Gumbiner B, Bulacan F, Brechtel G, Henry RR (1991) Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest 87:489–495PubMedCrossRef
25.
Zurück zum Zitat Lawrence JC, Roach PJ (1997) New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes 46:541–547PubMedCrossRef Lawrence JC, Roach PJ (1997) New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes 46:541–547PubMedCrossRef
26.
Zurück zum Zitat Villar-Palasi C, Guinovart JJ (1997) The role of glucose 6-phosphate in the control of glycogen synthase. FASEB J 11:544–558PubMed Villar-Palasi C, Guinovart JJ (1997) The role of glucose 6-phosphate in the control of glycogen synthase. FASEB J 11:544–558PubMed
27.
Zurück zum Zitat Skurat AV, Dietrich AD, Roach PJ (2000) Glycogen synthase sensitivity to insulin and glucose-6-phosphate is mediated by both NH2- and COOH-terminal phosphorylation sites. Diabetes 49:1096–1100PubMedCrossRef Skurat AV, Dietrich AD, Roach PJ (2000) Glycogen synthase sensitivity to insulin and glucose-6-phosphate is mediated by both NH2- and COOH-terminal phosphorylation sites. Diabetes 49:1096–1100PubMedCrossRef
28.
Zurück zum Zitat Hother-Nielsen O, Henriksen JE, Holst JJ, Beck-Nielsen H (1996) Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique. Metabolism 45:82–91PubMedCrossRef Hother-Nielsen O, Henriksen JE, Holst JJ, Beck-Nielsen H (1996) Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique. Metabolism 45:82–91PubMedCrossRef
29.
Zurück zum Zitat Bassett DR Jr, Howley ET, Thompson DL et al (2001) Validity of inspiratory and expiratory methods of measuring gas exchange with a computerized system. J Appl Physiol 91:218–224PubMed Bassett DR Jr, Howley ET, Thompson DL et al (2001) Validity of inspiratory and expiratory methods of measuring gas exchange with a computerized system. J Appl Physiol 91:218–224PubMed
30.
Zurück zum Zitat Frayn KN (1983) Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628–634PubMed Frayn KN (1983) Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628–634PubMed
31.
Zurück zum Zitat Tappy L, Owen OE, Boden G (1988) Effect of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes 37:1212–1216PubMedCrossRef Tappy L, Owen OE, Boden G (1988) Effect of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes 37:1212–1216PubMedCrossRef
32.
Zurück zum Zitat Jørgensen GM, Vind B, Nybo M, Rasmussen LM, Højlund K (2009) Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur J Endocrinol 161:95–101PubMedCrossRef Jørgensen GM, Vind B, Nybo M, Rasmussen LM, Højlund K (2009) Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur J Endocrinol 161:95–101PubMedCrossRef
33.
Zurück zum Zitat Birk JB, Wojtaszewski JF (2006) Predominant alpha2/beta2/gamma3 AMPK activation during exercise in human skeletal muscle. J Physiol 577:1021–1032PubMedCrossRef Birk JB, Wojtaszewski JF (2006) Predominant alpha2/beta2/gamma3 AMPK activation during exercise in human skeletal muscle. J Physiol 577:1021–1032PubMedCrossRef
34.
Zurück zum Zitat Lowry OH, Passonneau JV (1972) A flexible system of enzymatic analysis. Academic, London, pp 1–291 Lowry OH, Passonneau JV (1972) A flexible system of enzymatic analysis. Academic, London, pp 1–291
35.
Zurück zum Zitat Bouskila M, Hunter RW, Ibrahim AF et al (2010) Allosteric regulation of glycogen synthase controls glycogen synthesis in muscle. Cell Metab 12:456–466PubMedCrossRef Bouskila M, Hunter RW, Ibrahim AF et al (2010) Allosteric regulation of glycogen synthase controls glycogen synthesis in muscle. Cell Metab 12:456–466PubMedCrossRef
36.
Zurück zum Zitat Yki-Järvinen H, Mott D, Young AA, Stone K, Bogardus C (1987) Regulation of glycogen synthase and phosphorylase activities by glucose and insulin in human skeletal muscle. J Clin Invest 80:95–100PubMedCrossRef Yki-Järvinen H, Mott D, Young AA, Stone K, Bogardus C (1987) Regulation of glycogen synthase and phosphorylase activities by glucose and insulin in human skeletal muscle. J Clin Invest 80:95–100PubMedCrossRef
37.
Zurück zum Zitat Haugaard SB, Andersen O, Madsbad S et al (2005) Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired nonoxidative glucose disposal in HIV lipodystrophy. Diabetes 54:3474–3483PubMedCrossRef Haugaard SB, Andersen O, Madsbad S et al (2005) Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired nonoxidative glucose disposal in HIV lipodystrophy. Diabetes 54:3474–3483PubMedCrossRef
38.
Zurück zum Zitat Poulsen P, Poulsen P, Wojtaszewski JF et al (2005) Impact of genetic versus environmental factors on the control of muscle glycogen synthase activation in twins. Diabetes 54:1289–1296PubMedCrossRef Poulsen P, Poulsen P, Wojtaszewski JF et al (2005) Impact of genetic versus environmental factors on the control of muscle glycogen synthase activation in twins. Diabetes 54:1289–1296PubMedCrossRef
39.
Zurück zum Zitat Boström P, Andersson L, Vind BF et al (2010) The SNARE protein SNAP23 and the SNARE interacting protein Munc18c in human skeletal muscle are implicated in insulin sensitivity. Diabetes 59:1870–1878PubMedCrossRef Boström P, Andersson L, Vind BF et al (2010) The SNARE protein SNAP23 and the SNARE interacting protein Munc18c in human skeletal muscle are implicated in insulin sensitivity. Diabetes 59:1870–1878PubMedCrossRef
40.
Zurück zum Zitat Szendroedi J, Schmid AI, Chmelik M et al (2007) Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med 4:e154PubMedCrossRef Szendroedi J, Schmid AI, Chmelik M et al (2007) Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS Med 4:e154PubMedCrossRef
Metadaten
Titel
Hyperglycaemia normalises insulin action on glucose metabolism but not the impaired activation of AKT and glycogen synthase in the skeletal muscle of patients with type 2 diabetes
verfasst von
B. F. Vind
J. B. Birk
S. G. Vienberg
B. Andersen
H. Beck-Nielsen
J. F. P. Wojtaszewski
K. Højlund
Publikationsdatum
01.05.2012
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 5/2012
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2482-8

Weitere Artikel der Ausgabe 5/2012

Diabetologia 5/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.